Evaluation and cost assessment of fluoroquinolones in community-acquired respiratory infections

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 9, 2002, Pages 1251-1266

  Martin, Steven J ^a   Sahloff, Eric G ^a   Close, Sandy J ^a  

^a UNIVERSITY OF TOLEDO   (United States)

Author keywords

Acute exacerbation of chronic bronchitis; Community acquired pneumonia; Fluoroquinolones; Sinusitis

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFDINIR; CEFIXIME; CEFPODOXIME PROXETIL; CEFPROZIL; CEFTIBUTEN; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; CLARITHROMYCIN DERIVATIVE; COTRIMOXAZOLE; DIRITHROMYCIN; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; LORACARBEF; MACROLIDE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; CHRONIC BRONCHITIS; COMMUNICABLE DISEASE; CONTROLLED STUDY; CONVULSION; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG CHOICE; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; HEADACHE; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LONG QT SYNDROME; MANAGED CARE; PATHOGENESIS; PATIENT COMPLIANCE; PHOTOSENSITIVITY; PNEUMONIA; RESPIRATORY TRACT INFECTION; REVIEW; SINUSITIS; SLEEP DISORDER; VERTIGO;

EID: 0036724231     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.9.1251     Document Type: Review

References (85)

1. Expanded activity and utility of the new fluoroquinolones: A review
2. Guidelines for the management of adults with community-acquired pneumonia
3. A focus on acute sinusitis in adults: Changes in disease management
4. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease
5. The safety profile of the fluoroquinolones
6. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin
7. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes
8. Recognition and management of sinusitis
9. Acute community-acquired sinusitis
10. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis
11. Randomized controlled trial of 3 versus 10 days of trimethoprim/sulfamethoxazole for acute maxillary sinusitis
12. Healthcare expenditures for sinusitis in 1996: Contributions of asthma, rhinitis, and other airway disorders
13. Antibacterial treatment of otitis and sinusitis with ciprofloxacin and penicillin v - A comparison
14. Multicenter comparative trial of ciprofloxacin versus cefuroxime axetil in the treatment of acute rhinosinusitis in a primary care setting
15. Ciprofloxacin versus cefuroxime axetil in the treatment of adult patients with acute bacterial sinusitis
16. Comparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute sinusitis in adults
17. Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults
18. A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis
19. Efficacy and safety of oral levofloxacin compared with clarithromycin in the treatment of acute sinusitis in adults: A multicentre, double-blind, randomized study
20. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime in the treatment of acute bacterial sinusitis in adults
21. Gatifloxacin versus clarithromycin in the management of acute sinusitis
22. Treating acute, uncomplicated bacterial sinusitis with gatifloxacin
23. The efficacy and tolerability of moxifloxacin compared to trovafloxacin in the treatment of acute sinusitis
24. Data fact sheet
25. Guidelines for the treatment of acute exacerbations of chronic bronchitis
26. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis
27. The role of bacteria in exacerbations of COPD: A constructive review
28. Do bacteria cause exacerbations of COPD?
29. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease
30. Antibiotics in chronic obstructive pulmonary disease exacerbations: A meta-analysis
31. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD
32. Recommendations on the management of chronic bronchitis
33. Clinical studies in chronic bronchitis: A need for better definition and classification of severity
34. Antibiotic therapy in acute exacerbations of chronic bronchitis
35. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: Results from the TRUST surveillance program, 1999-2000
36. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States
37. Comparison of ciprofloxacin with ampicillin in acute infectious exacerbations of chronic bronchitis: A double-blind crossover study
38. Controlled prospective study of oral amoxicillin/clavulanate versus ciprofloxacin in acute exacerbations of chronic bronchitis
39. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: Ciprofloxacin 750 mg bid versus clarithromycin 500 mg bid
40. Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for the treatment of acute bacterial exacerbations of chronic bronchitis
41. Efficacy of oral ciprofloxacin versus clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis
42. The efficacy and safety of a new ciprofloxacin suspension compared with co-amoxiclav tablets in the treatment of acute exacerbations of chronic bronchitis
43. Efficacy and tolerability of twice-daily ciprofloxacin 750 mg in the treatment of patients with acute exacerbations of chronic bronchitis and pneumonia
44. Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis
45. Gatifloxacin treatment in patients with acute exacerbations of chronic bronchitis: Clinical trial results
46. Gatifloxacin versus cefuroxime axetil in patients with acute exacerbations of chronic bronchitis
47. Multicenter evaluation of the efficacy and safety of gatifloxacin in Mexican adult outpatients with respiratory tract infections
48. Gatifloxacin for acute exacerbations of chronic bronchitis: Community experience for TeqCES
49. Multicenter randomized study comparing the efficacy and safety of oral levofloxacin versus cefaclor in the treatment of acute bacterial exacerbations of chronic bronchitis
50. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis
51. Clinical effectiveness of levofloxacin in patients with acute exacerbations of chronic bronchitis: The relationship with in-vitro activity
52. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: Results of a randomized double-blind study
53. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis
54. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis
55. The safety and efficacy of short course (5-day) moxifloxacin versus azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis
56. Short-course moxifloxacin therapy for the treatment of acute bacterial exacerbations of chronic bronchitis
57. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis
58. The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: A Spanish physician and patient experience
59. Treatment outcomes in acute exacerbations of chronic bronchitis: Comparison of macrolides and moxifloxacin from the patient perspective
60. A 1-year community-based health economic study of ciprofloxacin versus usual antibiotic treatment in acute exacerbations of chronic bronchitis
61. Treatment cost of acute exacerbations of chronic bronchitis
62. Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis
63. Community-acquired pneumonia
64. Cost-effectiveness of gatifloxacin versus ceftriaxone with a macrolide for the treatment of community-acquired pneumonia
65. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia
66. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin
67. A controlled trial of a critical pathway for treatment of community-acquired pneumonia
68. Oral moxifloxacin versus high-dosage amoxicillin in the treatment of mild-to-moderate community-acquired pneumonia in adults
69. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia
70. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia
71. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia parenteral treatment
72. Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: Integrated results from four open-label, multicenter, Phase III clinical trials
73. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia
74. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia
75. Treating community-acquired pneumonia in hospitalized patients: Gatifloxacin versus ceftriaxone/clarithromycin
76. Treating community-acquired pneumonia with once-daily gatifloxacin versus twice-daily clarithromycin
77. Treating community-acquired pneumonia with once-daily gatifloxacin versus once-daily levofloxacin
78. New fluoroquinolones for treatment of community-acquired pneumonia (CAP): A meta-analysis
79. A critical review of the fluoroquinolones; focus on respiratory tract infections
80. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia
81. Medical outcomes and antimicrobial costs with the use of American Thoracic Society guidelines for outpatients with community-acquired pneumonia
82. Validation of the therapeutic recommendations of the American Thoracic Society (ATS) guidelines for community-acquired pneumonia in hospitalized patients
83. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia